Skip to main content
RXRX
NASDAQ Life Sciences

REC-4881 Cuts Larger, High-Risk Polyps Across GI Tract in Phase 2 FAP Data

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.827
Mkt Cap
$2.29B
52W Low
$2.77
52W High
$5.76
52W Position info
38% above low
Off High info
34% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

RXRX sits 38% above its 52-week low of $2.77.

Summary

Recursion presented new TUPELO Phase 2 analyses at the CGA-IGC meeting showing REC-4881 reduced polyp burden in the lower GI tract and shrank the larger polyps that drive most FAP surgeries. In the lower GI, 9 of 11 patients (82%) had reductions after 12 weeks, with a 50% median drop; six of eight patients had fewer polyps larger than 5 mm, and four saw counts fall by at least 80%. This builds on the upper GI results disclosed October 15, which is also when the company priced a $200M stock offering at $3.25 a share. Durability looks solid: 85% of patients remained below baseline at Week 25, 12 weeks off treatment, and no new safety signals appeared across 26 safety-evaluable patients. Management says the priority is aligning with the FDA on a registrational path, with a trial targeted for the second half of 2027 and more details expected later this year.

At the time of this announcement, RXRX was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.77 to $5.76. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

RXRX - Latest Insights

RXRX
Nov 02, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.82
Real-time Price: $2.92 info
Change: -$0.9043 (-24%) info
Market Cap: $1.811B info
RXRX
Nov 02, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.83
Real-time Price: $2.92 info
Change: -$0.914 (-24%) info
Market Cap: $1.811B info
RXRX
Nov 02, 2026, 4:31 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $2.92 info
Change: -$0.8843 (-23%) info
Market Cap: $1.811B info
RXRX
Oct 16, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $2.92 info
Change: -$1.25 (-30%) info
Market Cap: $1.811B info
RXRX
Oct 15, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $2.92 info
Change: -$0.804 (-22%) info
Market Cap: $1.811B info